Diabetes and ischemic heart disease (Q33762031)

29 July 2017

1 reference

title

Diabetes and ischemic heart disease (English)

1 reference

29 July 2017

coronary artery disease

1 reference

based on heuristic

inferred from title

author

Christopher B. Granger

series ordinal

2

object named as

Granger CB

1 reference

29 July 2017

1

McGuire DK

1 reference

PubMed ID

10539799

29 July 2017

language of work or name

English

0 references

publication date

1 November 1999

1 reference

29 July 2017

American Heart Journal

1 reference

29 July 2017

138

1 reference

29 July 2017

S366-75

1 reference

29 July 2017

5 Pt 1

1 reference

What cardiologists need to know about diabetes.

29 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970037-2

Cardiovascular complications of diabetes mellitus: what we know and what we need to know about their prevention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970037-2

Mechanisms determining course and outcome of diabetic patients who have had acute myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970037-2

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970037-2

Insulin and atheroma. 20-yr perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970037-2

Atherosclerosis in diabetes: the role of hyperinsulinemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970037-2

Relationship of plasma insulin levels to the incidence of myocardial infarction and coronary heart disease mortality in a middle-aged population.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970037-2

Hyperinsulinemia as an independent risk factor for ischemic heart disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970037-2

Hyperinsulinemia predicts coronary heart disease risk in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970037-2

Hyperinsulinemia does not increase the risk of fatal cardiovascular disease in elderly men or women without diabetes: the Rancho Bernardo Study, 1984-1991.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970037-2

Insulin and risk of cardiovascular disease: a meta-analysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970037-2

Lipids and lipoproteins predicting coronary heart disease mortality and morbidity in patients with non-insulin-dependent diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970037-2

Lipoprotein lipase. A multifunctional enzyme relevant to common metabolic diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970037-2

Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970037-2

Does glycemic control of type II diabetes suffice to control diabetic dyslipidemia? A community perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970037-2

Diabetes-induced alterations in platelet metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970037-2

Thromboxane biosynthesis and platelet function in type II diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970037-2

Diabetes, fibrinogen, and risk of cardiovascular disease: the Framingham experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970037-2

Effects of glucose and fatty acids on myocardial ischaemia and arrhythmias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970037-2

Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970037-2

Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970037-2

Outcome of patients with diabetes mellitus and acute myocardial infarction treated with thrombolytic agents. The Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970037-2

Enzymatic evidence of impaired reperfusion in diabetic patients after thrombolytic therapy for acute myocardial infarction: a role for plasminogen activator inhibitor?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970037-2

Angiographic Findings and Outcome in Diabetic Patients Treated With Thrombolytic Therapy for Acute Myocardial Infarction: The GUSTO-I Experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970037-2

Diabetic retinopathy should not be a contraindication to thrombolytic therapy for acute myocardial infarction: review of ocular hemorrhage incidence and location in the GUSTO-I trial. Global Utilization of Streptokinase and t-PA for Occluded Coronar

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970037-2

Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970037-2

Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. ETDRS Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970037-2

Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970037-2

A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970037-2

Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970037-2

Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970037-2

Beta-blockers and sudden cardiac death.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970037-2

Effects of metoprolol on mortality and late infarction in diabetics with suspected acute myocardial infarction. Retrospective data from two large studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970037-2

Timolol Treatment After Myocardial Infarction in Diabetic Patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970037-2

Diabetic patients and beta-blockers after acute myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970037-2

Effect on mortality of metoprolol in acute myocardial infarction. A double-blind randomised trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970037-2

Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970037-2

Acute myocardial infarction in diabetes mellitus: lessons learned from ACE inhibition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970037-2

Effect of the ACE inhibitor lisinopril on mortality in diabetic patients with acute myocardial infarction: data from the GISSI-3 study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970037-2

Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970037-2

Treatment of diabetic dyslipidemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970037-2

Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970037-2

Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970037-2

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970037-2

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970037-2

Glucose and the metabolism of ischaemic myocardium.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970037-2

Effects of an intravenous infusion of a potassium-glucose-insulin solution on the electrocardiographic signs of myocardial infarction. A preliminary clinical report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970037-2

Glucose-insulin-potassium therapy for treatment of acute myocardial infarction: an overview of randomized placebo-controlled trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970037-2

Diabetes and acute myocardial infarction: the role of insulin therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970037-2

Metabolic modulation of acute myocardial infarction. The ECLA (Estudios Cardiológicos Latinoamérica) Collaborative Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970037-2

Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970037-2

The sulfonylurea controversy: more questions from the heart

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970037-2

Does ischemic preconditioning occur in patients?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970037-2

Ischemic preconditioning during coronary angioplasty is prevented by glibenclamide, a selective ATP-sensitive K+ channel blocker.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970037-2

Oral sulfonylurea hypoglycemic agents prevent ischemic preconditioning in human myocardium. Two paradoxes revisited

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970037-2

Therapy of type 2 diabetes, cardiovascular death, and the UGDP

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970037-2

Exogenous insulin administration and cardiovascular risk in non-insulin-dependent and insulin-dependent diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970037-2

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970037-2

The effect of glycemic control on the incidence of macrovascular complications of type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970037-2

Hyperglycemia and microvascular and macrovascular disease in diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970037-2

The association of glycemia and cause-specific mortality in a diabetic population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970037-2

The effects of improved glycemic control on complications in type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970037-2

Long-term glycemic control relates to mortality in type II diabetes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970037-2

NIDDM and its metabolic control predict coronary heart disease in elderly subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970037-2

Lipids and lipoproteins as coronary risk factors in non-insulin-dependent diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970037-2

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0002-8703(99)70037-2

1 reference

29 July 2017

1 reference

PubMed ID

10539799